Published in Haemophilia on September 01, 2004
Barriers and perceived limitations to early treatment of hemophilia. J Blood Med (2013) 1.04
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood (2013) 1.02
Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus (2012) 0.91
Present and future challenges in the treatment of haemophilia: the patient's perspective. Blood Transfus (2013) 0.82
The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study. PLoS One (2016) 0.78
Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan. Yonsei Med J (2013) 0.76
Direct-to-consumer Marketing to People with Hemophilia. PLoS Med (2016) 0.75
Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment. Biotechnol Biotechnol Equip (2014) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet (1993) 9.88
Rosette-formation between human lymphocytes and sheep red cells not involving immunoglobulin receptors. Int Arch Allergy Appl Immunol (1970) 5.92
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med (1992) 3.21
Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst (1999) 3.13
Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology (1993) 2.64
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
Transmission of hepatitis C with pasteurised factor VIII. Lancet (1992) 2.62
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2005) 2.45
Test-retest variability in glaucomatous visual fields. Am J Ophthalmol (1989) 2.40
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med (1990) 2.25
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol (1998) 2.09
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost (2014) 2.02
Induction of crisis forms in the human malaria parasite Plasmodium falciparum by gamma-interferon-activated, monocyte-derived macrophages. J Immunol (1984) 1.95
Redistribution of membrane proteins in isolated mouse intestinal epithelial cells. J Cell Biol (1980) 1.94
Staging of bronchiolitis obliterans syndrome using home spirometry. Chest (1999) 1.86
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Validity of parental report of a child's medical history in otitis media research. Am J Epidemiol (1994) 1.75
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost (2012) 1.74
Informal and formal care among single-living elderly in Europe. Health Econ (2008) 1.73
Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst (1999) 1.73
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost (2007) 1.72
Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem (1995) 1.71
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2006) 1.70
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res (1996) 1.68
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control (2000) 1.61
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy (1991) 1.61
Local breast cancer recurrence caused by mammographically guided punctures. Acta Radiol (2000) 1.59
Mammographic screening for breast cancer. What cancers do we find? Eur J Cancer (1997) 1.58
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia (2007) 1.54
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med (2001) 1.54
Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost (2011) 1.54
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg (1988) 1.53
Diastolic blood pressure and area of residence: multilevel versus ecological analysis of social inequity. J Epidemiol Community Health (2001) 1.52
Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol (1997) 1.51
Prevalence and intensity of pain after stroke: a population based study focusing on patients' perspectives. J Neurol Neurosurg Psychiatry (2005) 1.48
Rhoptry secretion of membranous whorls by Plasmodium falciparum merozoites. Am J Trop Med Hyg (1986) 1.47
Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44
Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia (2002) 1.42
Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control (1999) 1.42
Community acquired Pseudomonas aeruginosa urinary tract infection in preschool children. Pediatr Nephrol (1997) 1.41
Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood (1992) 1.41
Addition of calcium to Euro-Collins solution is essential for 24-hour preservation of the vasculature. Ann Thorac Surg (1997) 1.41
Vitamin K antagonists and cancer: rebuttal. J Thromb Haemost (2004) 1.40
[Control of oral anticoagulant therapy. The Quick method is one step back]. Lakartidningen (1993) 1.40
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients. Haemophilia (2001) 1.40
[A complication in Budd-Chiari syndrome. Heparin therapy caused thrombocytopenia]. Lakartidningen (1994) 1.39
Vitamin B12 metabolism after urinary diversion with a Kock ileal reservoir. Scand J Urol Nephrol (2001) 1.39
Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ (1989) 1.39
An analysis of contact-service in the Migrant Health Service Referral System (MHSRS). Am J Public Health (1971) 1.38
Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun (1986) 1.37
Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol (1995) 1.34
Cancer of the nasal cavity and paranasal sinuses: a series of 115 patients. Rhinology (1998) 1.33
Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol (1989) 1.33
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet (2001) 1.32
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol (1999) 1.32
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med (1991) 1.30
Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J (1991) 1.28
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia (2002) 1.27
Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke (2001) 1.26
Nutrients and gastric cancer risk. A population-based case-control study in Sweden. Int J Cancer (1994) 1.25
Requirement for coenzyme Q in plasma membrane electron transport. Proc Natl Acad Sci U S A (1992) 1.25
Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis. Thromb Haemost (1984) 1.24
Perfusion-related parameters in intravoxel incoherent motion MR imaging compared with CBV and CBF measured by dynamic susceptibility-contrast MR technique. Acta Radiol (2001) 1.23
Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril (1994) 1.22
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia (2004) 1.19
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) (1985) 1.19
Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood (2001) 1.19
Early-life risk indicators of gastric cancer. A population-based case-control study in Sweden. Int J Cancer (1994) 1.17
Your next of kin or your own career? Caring and working among the 50+ of Europe. J Health Econ (2007) 1.17
Risk factors and treatment at recurrent stroke onset: results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovasc Dis (2008) 1.17
Five common fallacies in estimating the economic gains of early discharge. Soc Sci Med Med Econ (1980) 1.17
Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat (1996) 1.16
The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med (2000) 1.16
Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol (1995) 1.15
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost (2006) 1.14
The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res (1997) 1.14
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 1.14
Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand (1997) 1.14
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost (2009) 1.13
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism (1990) 1.12